Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

6 Months Ended

Jun. 30, 2023

Note 12 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Six months ended
		June 30,			June 30,
	2023		2022		2023		2022
Research and development	$	1,285	$	2,033	$	1,401	$	4,556
General and administrative		2,552		3,012		4,112		6,075
	$	3,837	$	5,045	$	5,513	$	10,631

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended				Six months ended
		June 30,				June 30,
	2023		2022			2023		2022
Number of options over ordinary shares granted		30,247,398		1,735,488		52,002,726		24,611,952
Weighted average fair value of ordinary shares options	$	0.05	$	0.25	$	0.08	$	0.41
Number of additional options with a nominal exercise price granted		6,148,186		3,361,728		26,015,098		21,050,160
Weighted average fair value of options with a nominal exercise price	$	0.15	$	0.34	$	0.17	$	0.55

The information above includes the impact of 29,654,742 options over ordinary shares and 5,501,602 options with a nominal exercise price granted on June 1, 2023, as replacement awards as part of the acquisition of TCR² Therapeutics Inc., as explained further in Note 15. The number and fair value of replacement awards of the Company granted to TCR² grantholders is provisional.